Citadel Advisors
MBRX icon

Citadel Advisors’s Moleculin Biotech MBRX Stock Holding History

Citadel Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,085
Closed -$110K – 13709
2025
Q4 		$110K Buy
+33,085
New +$308K ﹤0.01% 11558
2024
Q1 		– Sell
-172
Closed -$55.5K – 15127
2023
Q4 		$55.5K Buy
+172
New +$35.7K ﹤0.01% 11674
2023
Q2 		– Sell
-85
Closed -$30.6K – 14877
2023
Q1 		$30.6K Buy
85
+41
+93% +$18K ﹤0.01% 12716
2022
Q4 		$17.5K Buy
44
+8
+22% +$3.38K ﹤0.01% 13244
2022
Q3 		$14K Buy
+36
New +$20.8K ﹤0.01% 12177
2021
Q3 		– Sell
-101
Closed -$140K – 14320
2021
Q2 		$140K Buy
101
+64
+173% +$87.3K ﹤0.01% 12566
2021
Q1 		$56K Buy
+37
New +$67.8K ﹤0.01% 12849
2020
Q2 		– Sell
-16
Closed -$22K – 10224
2020
Q1 		$22K Buy
16
+7
+78% +$11.9K ﹤0.01% 9274
2019
Q4 		$19K Buy
+9
New +$21.1K ﹤0.01% 8944
2019
Q1 		– Sell
-10
Closed -$22K – 9634
2018
Q4 		$22K Buy
10
+5
+100% +$14.4K ﹤0.01% 8708
2018
Q3 		$18K Buy
+5
New +$18.8K ﹤0.01% 9028
2017
Q2 		– Sell
-8
Closed -$20K – 7829
2017
Q1 		$20K Buy
+8
New +$28K ﹤0.01% 7237

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM

Citadel Advisors's MBRX Position: Q1 2026 in Review

Citadel Advisors sold out of Moleculin Biotech (MBRX) in Q1 2026, closing a stake of 33,085 shares — an estimated $110K sold.

Citadel Advisors first reported a position in MBRX in Q1 2017 and held it in 12 quarters. The position peaked at $140K in Q2 2021. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Citadel Advisors reported no remaining Moleculin Biotech position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 33,085 Moleculin Biotech shares in Q1 2026, an estimated $110K.
  • Citadel Advisors first reported a position in Moleculin Biotech in Q1 2017 and held it in 12 quarters.
  • Citadel Advisors's Moleculin Biotech position peaked at $140K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.